학술논문
IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience.
Document Type
Article
Author
Source
Subject
*BLAST injuries
*MYELOFIBROSIS
*MYELOPROLIFERATIVE neoplasms
*HEMATOPOIETIC stem cell transplantation
*
*
*
Language
ISSN
0007-1048
Abstract
A total of 14 consecutive I IDH1/2 i -mutated patients with MPN-BP (median age 76 years) received ivosidenib ( I n i = 5) or enasidenib ( I n i = 9), either in the up-front ( I n i = 8) or relapsed ( I n i = 6) setting; one patient harboured both I IDH1 i and I IDH2 i mutations and received ivosidenib as front-line therapy followed by enasidenib at the time of relapse. Anaemia response was documented in five of 13 (38%) evaluable patients, which included two of four (50%) with CR/CRi; none of the patients with palpable splenomegaly displayed spleen response. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Figure 1A provides a timeline of treatment history, maximal response and duration of response for patients who achieved CR/CRi/PR. [Extracted from the article]